Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest update is out from BriaCell Therapeutics ( (TSE:BCT) ).
BriaCell Therapeutics has successfully closed its public offering, raising $3.05 million in gross proceeds through the sale of 762,500 common shares. The company plans to use the funds for working capital, general corporate purposes, and advancing its business objectives, marking an essential step in strengthening its financial position in the biotechnology sector.
More about BriaCell Therapeutics
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care.
YTD Price Performance: -50.86%
Average Trading Volume: 7,536
Technical Sentiment Consensus Rating: Buy
Current Market Cap: C$17.59M
For detailed information about BCT stock, go to TipRanks’ Stock Analysis page.
